Roquefort Investments PLC (LSE:ROQ) — Market Cap & Net Worth
Market Cap & Net Worth: Roquefort Investments PLC (ROQ)
Roquefort Investments PLC (LSE:ROQ) has a market capitalization of $184.27K (GBX1.51 Billion) as of May 5, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30845 globally and #1028 in its home market, demonstrating a 802.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Roquefort Investments PLC's stock price GBX9.25 by its total outstanding shares 163726294 (163.73 Million). Analyse cash efficiency ratio of Roquefort Investments PLC to see how efficiently the company converts income to cash.
Roquefort Investments PLC Market Cap History: 2021 to 2026
Roquefort Investments PLC's market capitalization history from 2021 to 2026. Data shows growth from $209.17K to $184.27K (6.48% CAGR).
Roquefort Investments PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Roquefort Investments PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.72x
Roquefort Investments PLC's market cap is 0.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $209.17K | $719.00 | -$917.43K | 290.92x | N/A |
| 2023 | $144.43K | $200.00K | -$1.74 Million | 0.72x | N/A |
Competitor Companies of ROQ by Market Capitalization
Companies near Roquefort Investments PLC in the global market cap rankings as of May 5, 2026.
Key companies related to Roquefort Investments PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Roquefort Investments PLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Roquefort Investments PLC's market cap moved from $209.17K to $ 184.27K, with a yearly change of 6.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX184.27K | +640.00% |
| 2025 | GBX24.90K | -69.14% |
| 2024 | GBX80.68K | -44.14% |
| 2023 | GBX144.43K | +9.43% |
| 2022 | GBX131.98K | -36.90% |
| 2021 | GBX209.17K | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Roquefort Investments PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $184.27K USD |
| MoneyControl | $184.27K USD |
| MarketWatch | $184.27K USD |
| marketcap.company | $184.27K USD |
| Reuters | $184.27K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more